Disclosed are means, methods, and compositions of matter useful for augmentation of a vaccine induced antitumor immune response through immunological targeting of tumor endothelium. In one embodiment a cancer antigen specific vaccine is combined with an endothelial targeting vaccine in a manner to facilitate release of tumor antigens as a result of endothelial destruction. The released tumor antigens serve to amplify immune response induced by the cancer antigen specific vaccine. In one embodiment an endogenous cancer vaccine is utilized as a source of immunization. The endogenous cancer vaccine may be cancer cells induced to die locally such as by means of: hyperthermia, irradiation, oncolytic virus exposure, and embolization.

The present invention is directed to methods of inducing a phenotypic change in a population of monocytes and/or macrophages. The method includes administering to the population of monocytes and/or macrophages, a macrophage stimulating agent coupled to a carrier molecule, wherein the carrier molecule facilitates macropinocytic uptake of the agent by monocytes and macrophages in the population and is defective in neonatal Fc receptor binding, wherein the administering induces a phenotypic change in the monocytes and macrophages in the population.

Described herein are methods of enriching and growing Type 2 innate lymphoid cells.

Cell culture systems for producing IL-33 induced T9 cells and methods of using the IL-33 induced T9 cells (T9.sub.IL-33 cells) in a cell therapy for increasing anti-tumoral activity following allogeneic hematopoietic cell transplantation (HCT) and/or treating graft-versus-host disease (GVHD) are disclosed herein. Further, methods of using the T9.sub.IL-33 cells, alone or in combination with allogeneic hematopoietic cell transplantation, are described herein for cancer treatment.

This invention concerns anti-inflammatory agents and methods for treating inflammatory disorders. Also disclosed are methods for identifying or evaluating anti-inflammatory agents or compositions.

The present invention provides methods of modulating of cancer immunity using type 2 innate lymphoid cells (IL-C2s), interleukin 33 (IL-33), IFI44 or combination thereof. Also provided are methods of preventing tumor metastasis and/or cancer progression by treatment with therapies comprising type 2 innate lymphoid cells (ILC2s), interleukin 33 (IL-33), IFI44 or combination thereof. Also provided are diagnostic methods for assessing cancer prognosis.

Compositions of matter, of production, and treatment modalities are disclosed for the prevention and/or therapeutic reduction of tumors through induction of immunity against tumor associated fibroblasts and components of tumor microenvironment. In one embodiment of the invention, placentally derived fibroblast cells are cultured under conditions replicating tumor microenvironment. Expression of CD248 on said cultured fibroblasts is used as a marker of effective manipulation. Cells expressing CD248 are utilized a immunogens for stimulation of immunity towards cancer associated fibroblastic cells.

The present invention provides methods of expanding T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded T cells and methods of using the expanded T cells (e.g., a part of an adoptive T cell therapy).

Disclosed are a method for producing a cell population in which regulatory T cells have proliferated, including (1) culturing a cell population containing CD4.sup.+ T cells derived from pluripotent stem cells in the presence of IL-4 and a TGF-R agonist, a cell population containing regulatory T cells obtained according to the method, and a medicine containing the cell population containing regulatory T cells.